Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Raw Materials (2016 - 2025)

Adma Biologics' Raw Materials history spans 10 years, with the latest figure at $96.6 million for Q4 2025.

  • For Q4 2025, Raw Materials rose 59.76% year-over-year to $96.6 million; the TTM value through Dec 2025 reached $96.6 million, up 59.76%, while the annual FY2025 figure was $96.6 million, 59.76% up from the prior year.
  • Raw Materials reached $96.6 million in Q4 2025 per ADMA's latest filing, up from $87.8 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $100.4 million in Q2 2025 to a low of $33.1 million in Q2 2021.
  • Average Raw Materials over 5 years is $57.4 million, with a median of $53.0 million recorded in 2023.
  • Peak YoY movement for Raw Materials: increased 4.35% in 2023, then surged 76.14% in 2025.
  • A 5-year view of Raw Materials shows it stood at $36.8 million in 2021, then soared by 32.34% to $48.6 million in 2022, then increased by 8.95% to $53.0 million in 2023, then rose by 14.1% to $60.5 million in 2024, then skyrocketed by 59.76% to $96.6 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Raw Materials are $96.6 million (Q4 2025), $87.8 million (Q3 2025), and $100.4 million (Q2 2025).